Developer docs
API playgroundTry for free, no card

Search company profiles

Insera Therapeutics

Full company profile

uuid0004rrx

Namestring
Insera Therapeutics
Legal namestring
Insera Therapeutics, LLC
Company typeenum
Private
Founded yearint
2012
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSacramento, United States
HQ citystring
Sacramento
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurovascular medical devices, stroke treatment devices, cerebral aneurysm devices, minimally invasive therapeutics, endovascular medical devices
Industry1 code
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurovascular Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical device sales (future commercialization)
TypeHardware Sales
Description

Insera Therapeutics is a medical device company developing innovative neurovascular products. As of the available source material, the company describes itself in product-development mode ("developing innovative products"), with a stated ambition to deliver products and services to patients worldwide. Commercial revenue model is therefore expected to be one-time/recurring hardware sales of FDA-cleared/approved medical devices to hospitals and clinical sites, though no explicit pricing, launch, or sales figures are disclosed in the source material.

inseratherapeutics.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Insera Therapeutics develops minimally invasive medical devices for the treatment of neurovascular diseases, with a focused portfolio spanning acute stroke treatment devices and cerebral aneurysm treatment devices. The company is positioned as a product-development-stage medical device maker targeting two of the highest-burden neurovascular conditions globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Targets a US stroke patient population of over 700,000 per year
+1 more record
Product overview1 text field

Insera Therapeutics, LLC is a Sacramento, CA-based medical devices company offering a focused portfolio of minimally invasive therapeutics for neurovascular diseases. Its products are organized around two core clinical focus areas — Acute Stroke Treatment Devices and Cerebral Aneurysm Treatment Devices — which together support the company's mission to be the most competitive and innovative provider of cures for neurovascular diseases through relentless, patient-focused innovation.

Product and service2 records
1Acute Stroke Treatment Devices
2Cerebral Aneurysm Treatment Devices
CategoryNeurovascular Medical Devices — Cerebral Aneurysm Treatment
Description

Minimally invasive medical devices developed by Insera Therapeutics for the treatment of cerebral aneurysms, complementing the company's neurovascular disease portfolio alongside its acute stroke treatment offerings. Target users are hospitals, neurosurgeons, and interventional neuroradiologists treating cerebral aneurysm patients.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeOthers
Description

Insera Therapeutics' corporate website is hosted by Turbify (a Yahoo! small-business hosting service). This is an operational website-hosting relationship, not a strategic commercial, technology, or financial partnership. Source: "Hosted by Yahoo! (Turbify)" footer on the homepage.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1MIVI Neuroscience
TypeEmerging player
Description

MIVI Neuroscience develops the Q Aspiration Catheter and other devices for ischemic and hemorrhagic stroke treatment. It is a relevant emerging peer targeting the same neurovascular hospital customer as Insera.

TypeDirect peer
Description

Penumbra is a pure-play neurovascular and peripheral vascular device company best known for its mechanical thrombectomy systems (Penumbra System, Indigo) and stroke aspiration catheters. It is the closest direct peer to Insera's acute stroke and aneurysm focus, with an endovascular, minimally invasive portfolio sold to the same interventional neuroradiology call point.

TypeBroad incumbent
Description

Stryker's Neurovascular division (built around the Target/Covidian acquisition) offers coils, stents, flow diverters, and Trevo thrombectomy devices for ischemic and hemorrhagic stroke. It is a broad incumbent in Insera's exact clinical indications, with global hospital sales coverage Insera would have to match.

TypeBroad incumbent
Description

Medtronic's Neurovascular business (acquired via Covidien) includes the Solitaire and React thrombectomy platforms and a full portfolio of coils and access devices. It competes head-to-head with Insera in acute ischemic stroke and aneurysm treatment through the same hospital channel.

5Johnson & Johnson (Cerenovus)
TypeBroad incumbent
Description

Cerenovus is J&J's neurovascular franchise, offering embolic coils, flow diverters (Pipeline), and revascularization devices. It is a broad incumbent directly overlapping Insera's stroke and aneurysm indications, with significant clinical evidence and KOL relationships.

TypeEmerging player
Description

Imperative Care is a venture-backed neurovascular company developing the Zoom aspiration catheter system and stroke thrombectomy devices. As an emerging challenger, it is highly comparable to where Insera aims to be — a focused neurovascular platform targeting the same hospital call point with next-generation devices.

TypeEmerging player
Description

Rapid Medical is an Israeli neurovascular device company developing Tigertriever (adjustable stroke thrombectomy device) and other minimally invasive aneurysm/stroke products. Its minimally invasive philosophy and indication overlap make it a relevant emerging peer to Insera.

TypeEmerging player
Description

Route 92 Medical is a privately held neurovascular company developing the FreeClimb and SuperBore catheter systems for mechanical thrombectomy. It is comparable as a venture-backed neurovascular startup focused on acute ischemic stroke intervention.

TypeEmerging player
Description

InNeuroCo is an early-stage neurovascular device company developing access and support catheters for stroke intervention. Its narrow focus and emerging status parallel Insera's profile and target the same interventional neuroradiology buyer.

TypeEmerging player
Description

Artio Medical is a private medical device developer focused on neurovascular and cardiovascular solutions, including flow diversion and aneurysm products. Its minimally invasive neurovascular portfolio and pre-commercial stage make it a useful emerging peer comparable to Insera.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Insera Therapeutics

Neurovascular Medical Devicesinseratherapeutics.com

Insera Therapeutics firmographics

Firmographics
Name
Insera Therapeutics
Legal name
Insera Therapeutics, LLC
Website
https://inseratherapeutics.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Insera Therapeutics industry classification

Industry
Product category
Neurovascular Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Neurovascular medical devices
  • Stroke treatment devices
  • Cerebral aneurysm devices
  • Minimally invasive therapeutics
  • Endovascular medical devices

Where Insera Therapeutics is headquartered

Location

Headquarters

HQ city
Sacramento
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Insera Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

  1. Medical device sales (future commercialization): Insera Therapeutics is a medical device company developing innovative neurovascular products. As of the available source material, the company describes itself in product-development mode ("developing innovative products"), with a stated ambition to deliver products and services to patients worldwide. Commercial revenue model is therefore expected to be one-time/recurring hardware sales of FDA-cleared/approved medical devices to hospitals and clinical sites, though no explicit pricing, launch, or sales figures are disclosed in the source material.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Insera Therapeutics product offering

Product offering

Core offering

Insera Therapeutics develops minimally invasive medical devices for the treatment of neurovascular diseases, with a focused portfolio spanning acute stroke treatment devices and cerebral aneurysm treatment devices. The company is positioned as a product-development-stage medical device maker targeting two of the highest-burden neurovascular conditions globally.

Product overview

Insera Therapeutics, LLC is a Sacramento, CA-based medical devices company offering a focused portfolio of minimally invasive therapeutics for neurovascular diseases. Its products are organized around two core clinical focus areas — Acute Stroke Treatment Devices and Cerebral Aneurysm Treatment Devices — which together support the company's mission to be the most competitive and innovative provider of cures for neurovascular diseases through relentless, patient-focused innovation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Acute Stroke Treatment Devices
  • Cerebral Aneurysm Treatment Devices Minimally invasive medical devices developed by Insera Therapeutics for the treatment of cerebral aneurysms, complementing the company's neurovascular disease portfolio alongside its acute stroke treatment offerings. Target users are hospitals, neurosurgeons, and interventional neuroradiologists treating cerebral aneurysm patients.

Quantifiable outcome

  • Targets a US stroke patient population of over 700,000 per year
  • +1 more outcomes

Companies that use Insera Therapeutics

Customer profile

Segments3 records

Ideal customer profiles1 record

Insera Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Insera Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Turbify (Yahoo!)minorOthersInsera Therapeutics' corporate website is hosted by Turbify (a Yahoo! small-business hosting service). This is an operational website-hosting relationship, not a strategic commercial, technology, or financial partnership. Source: "Hosted by Yahoo! (Turbify)" footer on the homepage.

Scale indicators4 records

Recent moves2 records

Expansion highlights3 records

Insera Therapeutics competitors and assessment

Company assessment

Emerging players

  • MIVI Neuroscience: MIVI Neuroscience develops the Q Aspiration Catheter and other devices for ischemic and hemorrhagic stroke treatment. It is a relevant emerging peer targeting the same neurovascular hospital customer as Insera.
  • Imperative Care: Imperative Care is a venture-backed neurovascular company developing the Zoom aspiration catheter system and stroke thrombectomy devices. As an emerging challenger, it is highly comparable to where Insera aims to be — a focused neurovascular platform targeting the same hospital call point with next-generation devices.
  • Rapid Medical: Rapid Medical is an Israeli neurovascular device company developing Tigertriever (adjustable stroke thrombectomy device) and other minimally invasive aneurysm/stroke products. Its minimally invasive philosophy and indication overlap make it a relevant emerging peer to Insera.
  • Route 92 Medical: Route 92 Medical is a privately held neurovascular company developing the FreeClimb and SuperBore catheter systems for mechanical thrombectomy. It is comparable as a venture-backed neurovascular startup focused on acute ischemic stroke intervention.
  • InNeuroCo: InNeuroCo is an early-stage neurovascular device company developing access and support catheters for stroke intervention. Its narrow focus and emerging status parallel Insera's profile and target the same interventional neuroradiology buyer.
  • Artio Medical: Artio Medical is a private medical device developer focused on neurovascular and cardiovascular solutions, including flow diversion and aneurysm products. Its minimally invasive neurovascular portfolio and pre-commercial stage make it a useful emerging peer comparable to Insera.

Direct peers

  • Penumbra, Inc. Penumbra is a pure-play neurovascular and peripheral vascular device company best known for its mechanical thrombectomy systems (Penumbra System, Indigo) and stroke aspiration catheters. It is the closest direct peer to Insera's acute stroke and aneurysm focus, with an endovascular, minimally invasive portfolio sold to the same interventional neuroradiology call point.

Broad incumbents

  • Stryker (Neurovascular): Stryker's Neurovascular division (built around the Target/Covidian acquisition) offers coils, stents, flow diverters, and Trevo thrombectomy devices for ischemic and hemorrhagic stroke. It is a broad incumbent in Insera's exact clinical indications, with global hospital sales coverage Insera would have to match.
  • Medtronic (Neurovascular): Medtronic's Neurovascular business (acquired via Covidien) includes the Solitaire and React thrombectomy platforms and a full portfolio of coils and access devices. It competes head-to-head with Insera in acute ischemic stroke and aneurysm treatment through the same hospital channel.
  • Johnson & Johnson (Cerenovus): Cerenovus is J&J's neurovascular franchise, offering embolic coils, flow diverters (Pipeline), and revascularization devices. It is a broad incumbent directly overlapping Insera's stroke and aneurysm indications, with significant clinical evidence and KOL relationships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key highlights5 records

Customer concentration

Insera Therapeutics social profiles

Digital presence

Insera Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Insera Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Insera Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Insera Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Insera Therapeutics

What does Insera Therapeutics do?

Insera Therapeutics develops minimally invasive medical devices for the treatment of neurovascular diseases, with a focused portfolio spanning acute stroke treatment devices and cerebral aneurysm treatment devices. The company is positioned as a product-development-stage medical device maker targeting two of the highest-burden neurovascular conditions globally.

Is Insera Therapeutics a public or private company?

Insera Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Insera Therapeutics founded?

Insera Therapeutics was founded in 2012. It employs 1 to 10 people.

Where is Insera Therapeutics based?

Insera Therapeutics is headquartered in Sacramento, United States, in the North America region.

How does Insera Therapeutics make money?

One revenue line is on record: medical device sales (future commercialization).

Who are Insera Therapeutics's main competitors?

Emerging players on record are MIVI Neuroscience, Imperative Care, Rapid Medical, Route 92 Medical, InNeuroCo and Artio Medical. Penumbra, Inc. is listed as a direct peer. Broad incumbents are Stryker (Neurovascular), Medtronic (Neurovascular) and Johnson & Johnson (Cerenovus).

Does Insera Therapeutics have an API?

No public API is recorded for Insera Therapeutics.

What industry is Insera Therapeutics in?

Insera Therapeutics's product category is Neurovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireInsera Therapeutics, Inc. Receives U.S. FDA 510(k) Clearance for the CLEAR™ Aspiration System Featuring Cyclical AspirationInsera Therapeutics received FDA 510(k) clearance for its CLEAR Aspiration System, a digital aspiration platform for removing fresh emboli and thrombi from peripheral arterial and venous systems. The system includes a pump and disposables, and the company holds 108 patent filings, including 100 issued or allowed patents.VenousnewsInsera announces first-in-human treatment of patient with PE using CLEAR aspiration systemInsera Therapeutics has successfully treated the first patient with acute pulmonary embolism using its CLEAR aspiration system. The patient, a 65-year-old man, was in critical condition due to right-sided heart failure caused by large blood clots, where traditional treatments were contraindicated. This milestone follows the recent positive results of the EXTRACT-PE trial and highlights the potential for innovative treatments in managing life-threatening blood clots.VascularnewsInsera announces first two stroke patients treated with its cyclical aspiration systemInsera Therapeutics has announced that it successfully treated its first two ischaemic stroke patients using its CLEAR Aspiration System. The device, which received CE mark approval in March 2019, demonstrated safety and efficacy benefits, achieving complete vessel re-opening in a matter of minutes for the first patient.NeuroNewsInsera earns CE mark approval for cyclical-suction stroke thrombectomy platform, the CLEAR aspiration systemInsera Therapeutics has received CE mark approval for its CLEAR Aspiration System, which is used for the aspiration of blood clots in patients with acute ischemic stroke and related conditions. This innovative system allows for varying vacuum suction pressures, enhancing the effectiveness of clot removal compared to traditional methods. The approval follows comprehensive testing at leading stroke device centers in the USA, highlighting the system's safety and efficacy.